Cancer is a scourge on society. One in two Americans will be diagnosed with cancer during their lifetime and one in five will die. The five-year cancer survival rates approach 90% when diagnosed in the earliest stages of the disease versus just 10% in the latest stages.
We believe it doesn’t have to be this way.
Assembled a deep clinical evidence library with data collected from more than 1,200 subjects
More than 20 premier cancer institutions around the world participated in our clinical trials
IONIQ's ProLung Test was awarded “Breakthrough Device Designation” by US FDA for its life-enhancing potential
Robust, growing intellectual portfolio of patents and know-how
The Utah Business magazine has recently featured IONIQ Sciences, highlighting everything from the “breakthrough” status of our IONIQ ProLung Test™ to the encouraging early results of our ongoing breast feasibility study. The article describes our key involvement with BioHive and the success we’ve had attracting world-renowned experts to help us detect
Salt Lake City, UT, March 30, 2021 – IONIQ Sciences, Inc. (“IONIQ” or the “Company”), is developing a rapid and non-invasive multi-cancer screen for early detection that has the potential to expand the therapeutic window, dramatically improve survivability and reduce the cost of healthcare. Today
More Breaking news from IONIQ Sciences! Did you know multi-cancer screens are not covered by Medicare? Did you know seniors are disproportionately affected by cancer? Did you know early cancer detection saves lives and healthcare money? IONIQ Sciences, Inc. is honored to be joined by more
